Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
REVENUES:        
Government contract revenue $ 0 $ 0 $ 149,625 $ 0
Total revenues 0 0 149,625 0
OPERATING EXPENSES        
Professional fees 403,044 383,178 852,479 726,201
Payroll and related expenses 672,279 618,081 1,274,844 1,248,308
General and administrative 271,631 234,914 466,528 421,913
Total operating expenses 1,346,954 1,236,173 2,593,851 2,396,422
OPERATING LOSS (1,346,954) (1,236,173) (2,444,226) (2,396,422)
OTHER EXPENSE        
Interest and other debt expenses 55,106 61,979 110,210 250,583
Loss on share for warrant exchanges 0 10,425 0 130,214
Loss on debt extinguishment 0 0 0 376,909
Total other expense 55,106 72,404 110,210 757,706
NET LOSS (1,402,060) (1,308,577) (2,554,436) (3,154,128)
LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS (8,715) (4,671) (14,864) (8,439)
NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC. $ (1,393,345) $ (1,303,906) $ (2,539,572) $ (3,145,689)
BASIC AND DILUTED LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS $ (0.08) $ (0.14) $ (0.14) $ (0.35)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED 17,789,236 9,032,157 17,771,918 8,939,624